OncLive TV

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia.

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses immunotherapy in triple-negative breast cancer.

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the first annual Luminary Awards in GI Cancers, which is honoring five individuals who have devoted their time, talent and resources to improving the care for patients and families affected by GI cancers.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma.

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses combining chemotherapy and immunotherapy as a treatment approach for patients with bladder cancer.

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, discusses the management of elderly patients with chronic lymphocytic leukemia (CLL).

Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, discusses approaching patients with HPV-positive head and neck cancer.

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses comparing agents in multiple myeloma.

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses a study evaluating the IDO1 inhibitor BMS-986205 as a monotherapy and in combination with nivolumab in patients with advanced cancers.

Ferdinandos Skoulidis, MD, PhD, MRCP, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses combining chemotherapy and immunotherapy in non-small cell lung cancer (NSCLC).

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, advises physicians on considering secondary cytoreductive surgery in ovarian cancer.

Julien Taieb, MD, head of the gastroenterology and gastrointestinal oncology department of the Georges Pompidou European Hospital, Paris Descartes University, discusses sidedness in metastatic colon cancer.

Peter Soyer, MD, academic dermatologist, professor, The University of Queensland Diamantina Institute, discusses screening for melanoma.

Alice S. Mims, MD, assistant professor of medicine, The Ohio State University Comprehensive Cancer Center, discusses momelotinib in patients with myelofibrosis.

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the future of immunotherapy combinations for patients with melanoma.

Jayesh Mehta, MD, professor of medicine (hematology and oncology), Feinberg School of Medicine, discusses stem cell transplant in multiple myeloma.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses central nervous system penetration in the treatment of non-small cell lung cancer.

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco (UCSF), discusses the future of imaging for biochemical recurrent prostate cancer.

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), discusses the MA.17R study for patients with breast cancer.

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses unmet needs facing patients with colorectal cancer (CRC).

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center discusses biomarkers for immunotherapy in patients with bladder cancer.

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.

Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the ATEMPT trial for patients with HER2-positive breast cancer.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the toxicity profile seen with nivolumab versus ipilimumab for patients with melanoma.

Bert O'Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses left-sided versus right-sided colorectal cancer (CRC).